Green Tea Ginger Flavor for Digestive Wellbeing

Clinical Study to Evaluate the Safety and Efficacy of Green Tea, Ginger Flavor for digestive wellbeing - Randomized Open Label Phase II Comparative Clinical Studyâ??

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2018/02/011860

Enrollment

Registered

2018-02-12

Start date

Unknown

Completion date

Unknown

Last updated

2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: null- Digestive Wellbeing

Interventions

Intervention1: Green Tea Ginger Flavor: 1 tea bag (2 g) in 150 ml of boiling water twice daily for a period of two weeks Control Intervention1: Regular Tea of Subjects choice: 1 cup twice daily only f

Eligibility

Inclusion criteria

Inclusion criteria: 1. Both male and females in the age group of 18 - 60 years 2. Subjects who have mild occasional symptoms like abdominal discomfort, heartburn, flatulence, abdominal distension, belching, nausea, vomiting, sense of fullness/heaviness of stomach etc 3. Subjects willing to give written informed consent 4. Subjects who are willing to maintain their regular diet pattern and refrain from any other beverages known to relieve digestive disturbances 5. Subjects who have not participated in similar kind of study in last 4 weeks

Exclusion criteria

Exclusion criteria: 1. Subjects with chronic gastrointestinal disorders and had undergone any surgery 2. Subjects with chronic infection 3. Subjects who are on anti-allergic or anti- inflammatory medications 4. Subjects with established hypertension, renal, hepatic or cardiac failure 5. Subjects with endocrine disorders 6. Subjects currently using prescription medication to treat gastric problems 7. Subjects who are pregnant & lactating women. 8. Subjects who are not willing to sign informed consent form

Design outcomes

Primary

Measure	Time frame
Significant reduction from mild occasional abdominal discomfort, heartburn, flatulence, abdominal distension, belching, nausea, vomiting, sense of fullness/heaviness of stomachTimepoint: Screening End of First Week End of Second Week (End of the study)	—

Secondary

Measure	Time frame
Assessment of any adverse events/serious adverse events neither observed or reported Improvement in the quality of lifeTimepoint: Screening and at the end of Week 2	—

Countries

India

Contacts

Public ContactDr Srikrishna H A

The Himalaya Drug Company Ltd

dr.palani@himalayawellness.com

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026